Details for New Drug Application (NDA): 012657
✉ Email this page to a colleague
The generic ingredient in CELESTONE is betamethasone acetate; betamethasone sodium phosphate. There are sixty-six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the betamethasone acetate; betamethasone sodium phosphate profile page.
Summary for 012657
Tradename: | CELESTONE |
Applicant: | Schering |
Ingredient: | betamethasone |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 012657
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 0.6MG | ||||
Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No |
Expired US Patents for NDA 012657
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Schering | CELESTONE | betamethasone | TABLET;ORAL | 012657-003 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription